Brief: Transgene & NEC Bio Sign License Agreement To Prepare Next Steps Of Development Of TG4050 In Head & Neck Cancer
02/04/2026 18:35
April 2 (Reuters) - Transgene SA TRNG.PA: TRANSGENE AND NEC BIO SIGN LICENSE AGREEMENT TO PREPARE THE NEXT STEPS OF THE DEVELOPMENT OF TG4050 IN HEAD AND NECK CANCER TRANSGENE SA - NEW SHARES WILL REPRESENT 1.22% OF TRANSGENE SHARE CAPITAL AND 0.98% OF VOTING RIGHTS TRANSGENE: NEC WILL RECEIVE TECHNOLOGY ACCESS FEE OF EUR 2.5 MILLION IN TRANSGENE SHARES, EUR 2.5 MILLION IN CASH TRANCHES THROUGH EARLY 2028 Source text: ID:nGNX4nG27d Further company coverage: TRNG.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transgene SA
See all newsFrance's Transgene H1 operating income falls on lower tax credit
Transgene jumps 20% on positive cancer vaccine data in early trial
Brief: Transgene & NEC Bio Sign License Agreement To Prepare Next Steps Of Development Of TG4050 In Head & Neck Cancer
Brief: Transgene SA Says Myvac Platform To Initiate Phase 1 Trial In Second Indication In 2026
France's Transgene 2025 net loss widens on higher financial costs